DME

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Results showed an unequal distributions of these clinical trials among rural and low-income populations.

VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

The investigators conducted a prospective interventional study to determine the therapeutic anatomic and functional effects of one intravitreal dexamethasone implant in eyes with refractory diabetic macular edema.

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving healthy ones intact.

After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue.

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

24-week topline data from the phase 2b ASPIRE study in diabetic macular edema (DME) are expected to be released in Q1 of 2025.

The database comprises 879 eyes, aged 22-84, collected across 9 clinical sites.

Visual acuity with both approaches was comparable and the device was efficacious and safe.

A recent study of AEYE-DS AI technology used in conjunction with the Topcon NW500 resulted in exceptional clinical diagnostic efficacy.

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

ARCATUS or ARVN001, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries is formally known as XIPERE in the United States and was developed by Clearside Biomedical.

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in 3 cohorts.

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for the treatment of diabetic macular edema in October 2024.

Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab compared with aflibercept in patients with DME.

Enhancing durability and reducing treatment burden.

Researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of diabetic macular edema (DME).

Early results suggest participant diversity and novel measures will enable new, artificial intelligence-driven insights. As the study evolves, it could lead to significant advancements in understanding how environmental exposures contribute not only to diabetes but also to its complications, including those affecting eye health, such as diabetic retinopathy.

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15.

To educate the public—including parents, caregivers, and allied health professionals—Prevent Blindness is offering free educational resources, including fact sheets, social media graphics, web pages, and educational videos in both English and Spanish.

The Gr8 Eye Movement campaign by Prevent Blindness and Regeneron emphasizes the critical role of caregivers in eye health, revealing significant gaps in caregivers' awareness of retinal diseases and aging-related vision loss.

According to the company, Duravyu 2.7 mg demonstrated an early and sustained anatomical improvement mirroring BCVA results with a 68 micron reduction in CST. Full topline data is anticipated in Q1 of 2025.

Ophthalmologists discuss advancing treatment strategies to improve outcomes.